Pending EO 12866 Regulatory Review
RIN: 0910-ZB96 | Received Date: 04/10/2024 |
Title: Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies; Guidance for Industry | |
Agency/Subagency: HHS / FDA | Stage: Notice |
Legal Deadline: None | Section 3(f)(1) Significant: No |
International Impacts: No | Affordable Care Act [Pub. L. 111-148 & 111-152]: No |
Pandemic Response: No | Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No |